Board of Directors

Elected to the Board 2005 and 2019

Born: 1966

Education: BSc Business and Economics, Stockholm School of Economics.

Background: CEO of EQT. Co-founder of Bactiguard and Chairman of the Board 2005–2015 and 2019–2023. Partner and CEO of private equity firm EQT.

Other assignments: Special advisor EQT. Investor, owner, and Board Member of A3P, Smartcella Holding AB, and TomEnterprise AB.

Shareholdings: 2,000,000 A-shares, 4,604,182 B-shares and 1,785,384* B-shares via a capital insurance with a company, controlled by Thomas von Koch, as beneficiary (* holding per 31 March 2024).

Elected to the Board 2023

Born: 1957

Education: Studies at Miami University, MD Case Western Reserve University School of Medicine. Residency/chief residency internal medicine at University of Texas Southwestern Medical School, Parkland Hospital. Fellowships cardiovascular diseases/interventional cardiology at Harvard Medical School and Beth Israel Hospital. MSc in Biostatistics Harvard T.H. Chan School of Public Health.

Previous assignments: CMO/SO Medtronic, PLC. Founder/CSO of Harvard Clinical Research Institute, Boston. Assoc. Professor of Medicine Harvard Medical School, Chief of Division of Clinical Biometrics, and Interventional Cardiologist of cardiovascular diseases division at Brigham and Women’s Hospital, Boston.

Other assignments: Board Member of ZimVie Inc., Identiv Inc., and Cognito Therapeutics, Inc.

Shareholdings: 121,655 call options.

Independent in relation to the Company and its management and the Company’s major shareholders.

Elected to the Board 2019

Born: 1969

Education: MD, Ph.D, Karolinska Institutet,  Board Certified Surgeon.

Previous assignments: Dean Campus North, Karolinska Institutet, Member of the Faculty Board and Board of Research at Karolinska Institutet.

Other assignments (select): Professor of Surgery, Karolinska Institutet, Senior Consultant Surgeon, Karolinska University Hospital, Scientific Director Life Science, Karolinska Institutet. Board member of Radiumhemmets Forskningsfonder, Research!Sweden and Genomic Medicine Sweden.

Shareholdings: 2,600 B-shares as personal holdings and 28,818 call options.

Independent in relation to the Company and its management and the Company’s major shareholders.

Elected to the Board 2022

Born: 1971

Education: Master’s degree in international economics and licentiate degree in industrial economics from Linköping University.

Previous assignments: Former CEO of Interflora and SamSari, as well as several roles within Microsoft and WM Data. Digitization as a core competence. Former Chairman of the Board of Affecto Plc, Nexon Asia Pacific and Iver Holding AB.

Other assignments: Chairman of the Board of SK Shieldus (South Korea), Board Member of NCAB Group, Recover Nordic Group and Qarlbo AB, as well as advisor to private equity firm EQT.

Shareholdings: 28,818 call options.

Independent in relation to the Company and its management and the Company’s major shareholders.

Elected to the Board 2018

Born: 1962

Education: BSc Business and Economics, Stockholm School of Economics. Studies at the MBA program at New York University, Stern School of Business.

Previous assignments: Partner, Deputy CEO and Deputy Chairperson of private equity firm EQT.

Other assignments: Board member of Trelleborg AB and ITB-Med AB. Founder and CEO of Trill Impact AB.

Shareholdings: 3,605,150 B shares as personal holdings.